股票代码：002019 证券简称：亿帆医药 公告编号：2025- 030 亿帆医药股份有限公司 亿帆医药股份有限公司定于2025年5月8日（星期四）15:00-17:00在全景网举 办2024年度网上业绩说明会，本次年度业绩说明会将采用网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年度 业 绩 说 明 会 或 者 直 接 进 入 亿 帆 医 药 股 份 有 限 公 司 路 演 厅 （https://ir.p5w.net/c/002019.shtml）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼总裁程先锋先生、副总裁耿雨红女 士、财务总监张大巍先生、董事兼副总裁林行先生、独立董事曾玉红女士、董事、 副总裁兼董事会秘书冯德崎先生等。 为充分尊重投资者、提升交流的针对性，现就公司2024年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2025年5月 6日（星期二）17:00前访问https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征 集专题页面。公司将在2024年度业绩说明会上，对投 ...

| 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 程先锋 | 12413.16 | 14.75 | 不变 | | 香港中央结算有限公司 | 2411.40 | 2.87 | -898.88 | | 郑珍 | 1534.91 | 1.82 | 16.15 | | 黄小敏 | 1106.18 | 1.31 | 不变 | | 中国农业银行股份有限公司-中证500交易型开放式指数证券 投资基金 | 1064.36 | 1.26 | 新进 | | 方铭 | 901.30 | 1.07 | -0.01 | | 上海银行（601229）股份有限公司-银华中证创新药产业交 易型开放式指数证券投资基金 | 832.78 | 0.99 | 新进 | | 上海迎水投资管理有限公司-迎水潜龙13号私募证券投资基 | | | | | 金 | 823.00 | 0.98 | 不变 | | 上海迎水投资管理有限公司-迎水巡洋4号私募证券投资基金 | 822.00 | 0.98 | 不变 | | 上海迎水投资管理有限公司-迎水和谐 ...

亿帆医药股份有限公司 关于召开 2024 年年度股东会的通知 亿帆医药股份有限公司（以下简称"公司"）第八届董事会第十六次会议决 定于2025年5月20日（星期二）召开2024年年度股东会。 一、召开会议的基本情况 1、股东会届次：2024年年度股东会 证券代码：002019 证券简称：亿帆医药 公告编号：2025-031 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2、股东会召集人：公司董事会 2025年4月24日召开的第八届董事会第十六次会议以8票同意、0票反对、0 票弃权的结果，审议通过了《关于召开2024年年度股东会的议案》。 3、会议召开的合法、合规性 本次股东会的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 4、会议召开的日期、时间 现场会议召开的时间：2025 年 5 月 20 日下午 1:30 起 网络投票的时间：2025 年 5 月 20 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为2025年5月 20日上午9:15至9:25，9:30至11:30，下午13:00至15:00； 通过深圳证券交易 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2025-019 亿帆医药股份有限公司 经与会监事认真审议，会议以投票表决的方式形成以下决议： （一）会议以3票同意，0票反对，0票弃权的结果，审议通过了《公司2024 年度监事会工作报告》 具体内容详见公司于同日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《2024年度监事会工作报告》。本议案需提交2024年年度股东会审议。 （二）会议以3票同意，0票反对，0票弃权的结果，审议通过了《公司2024 年年度报告及其摘要》 经审核，监事会认为：公司董事会编制和审核《2024年年度报告》和《2024 年年度报告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容真 实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 （三）会议以3票同意，0票反对，0票弃权的结果，审议通过了《关于公司 2024年度利润分配预案的议案》 第八届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 亿帆医药股份有限公司（ ...

亿帆医药股份有限公司 第八届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 亿帆医药股份有限公司（以下简称"公司"）第八届董事会第十六次会议 于2025年4月14日以邮件的方式发出通知，于2025年4月24日以现场加通讯表决 的方式在公司一楼会议室召开，其中以通讯表决方式参加会议的董事为林行先 生、GENHONG CHENG先生。会议应出席董事8名，实际出席董事8名，会议 由董事长程先锋先生主持，公司监事及高级管理人员列席会议。本次会议的召 集和召开符合《公司法》和《公司章程》等有关规定。 证券代码：002019 证券简称：亿帆医药 公告编号：2025-018 二、董事会会议审议情况 经全体董事认真审议，会议以投票表决的方式形成以下决议： （一）会议以8票同意、0票反对、0票弃权的结果，审议通过了《公司 2024年度总裁工作报告》 （二）会议以8票同意、0票反对、0票弃权的结果，审议通过了《公司 2024年度董事会工作报告》 《2024年 度 董 事 会 工 作 报 告 》 详 见 公 司 同 日 在 巨 潮 ...

亿帆医药股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第八届 董事会第十六次会议及第八届监事会第十三次会议，均审议通过了《关于公司 2024 年度利润分配预案的议案》，本议案尚需提交公司 2024 年年度股东会审议， 现将有关情况公告如下： 二、本次利润分配预案的基本情况 1、公司 2024 年度可分配利润情况 证券代码：002019 证券简称：亿帆医药 公告编号：2025- 021 亿帆医药股份有限公司 关于公司 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 2024 年半年度，公司进行了现金分红，以公司现有总股本 1,226,024,827 股 扣除回购专户上已回购股份 9,634,742 股后的总股本 1,216,390,085 股为基数，向 全体股东每 10 股派现金 1 元（含税），共计派发现金 121,639,008.50 元，不送 红股，不以资本公积金转增股本。即 2024 年度，公司累计现金分红总额为 243,278,017.00 元。 经立信会计师事务所（特殊普通合伙） ...

Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares to all shareholders, based on a total of 1,216,390,085 shares[4]. - The board has approved a profit distribution plan that does not include stock dividends or capital reserves conversion[4]. - The total cash dividend amount, including other methods, is 402,265,883.37 yuan, which accounts for 100% of the total profit distribution[198]. - The cash dividend policy was strictly adhered to, with clear standards and procedures in place to protect shareholder interests[197]. - The cash dividend distribution plan is subject to approval at the company's 2024 annual general meeting[200]. - The company has implemented a cash dividend distribution for the first half of 2024, with the same terms as the annual plan[200]. - The total number of shares after deducting repurchased shares is 1,216,390,085 shares for the dividend calculation[200]. Financial Performance - The company's operating revenue for 2024 reached ¥5,159,823,227.64, representing a 26.84% increase compared to ¥4,068,107,333.94 in 2023[18]. - Net profit attributable to shareholders for 2024 was ¥385,967,572.95, a significant turnaround from a loss of ¥551,073,063.61 in 2023, marking a 170.04% increase[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥248,094,095.26, up 146.58% from a loss of ¥532,628,603.81 in the previous year[19]. - Basic earnings per share for 2024 were ¥0.32, compared to a loss of ¥0.45 in 2023, reflecting a 171.11% increase[18]. - The net cash flow from operating activities increased by 83.81% to ¥640,730,192.65, up from ¥348,584,791.89 in 2023[19]. - Total assets at the end of 2024 were ¥12,285,788,088.75, a 6.84% increase from ¥11,499,585,782.14 at the end of 2023[18]. - The net assets attributable to shareholders increased by 2.98% to ¥8,521,867,867.56 at the end of 2024, compared to ¥8,275,633,622.03 at the end of 2023[18]. Revenue Growth and Sources - The company attributed revenue growth to the approval and sales increase of self-developed and imported pharmaceutical products[18]. - The company received government subsidies related to revenue, contributing to the increase in net profit[19]. - Total revenue for the year was approximately CNY 5.16 billion, with a quarterly breakdown showing Q1 at CNY 1.33 billion, Q2 at CNY 1.31 billion, Q3 at CNY 1.23 billion, and Q4 at CNY 1.30 billion[23]. - The company reported a total of CNY 122.15 million in government subsidies for the year, a substantial increase from CNY 41.81 million in the previous year[25]. Market Position and Product Development - Vitamin B5 remains a key product for the company, maintaining a leading position in its niche market despite competitive pressures[34]. - The company is focusing on enhancing operational efficiency and supply chain management to maintain competitive advantages in the vitamin market[34]. - The company has established a high-standard production system for macromolecular drugs that meets the quality requirements of various countries, having passed GMP certifications from NMPA, FDA, and EMA[38]. - The company has successfully commercialized its innovative biological drug, Yilishu, in 34 countries including China, the United States, and the EU[38]. - The company is focusing on developing new products tailored for children's physiological characteristics to enhance the safety and effectiveness of pediatric medications[42]. - The company is positioned as a leader in the vitamin market, with a significant presence in animal nutrition and food additives, driven by a recovery in consumer demand[35]. Research and Development - The company will continue to increase R&D investment to discover, develop, and commercialize drugs that meet unmet clinical needs, in line with the national strategy for innovative drug development[44]. - The company aims to optimize its product portfolio and implement comprehensive measures to adapt to the challenges posed by the reform of medical insurance payment methods, ensuring sustainable development[44]. - The company plans to improve clinical trial design and data analysis to enhance the efficiency of new drug development and accelerate market access[48]. - The company is actively enhancing its international business team to expand its product portfolio through licensing transactions[38]. - The company is focused on increasing its core competitiveness through innovative drug development and international expansion strategies[98]. Risk Management - The company has outlined various risks in its operations, including international trade risks and R&D performance risks[4]. - The company reported uncertainty regarding its ability to continue as a going concern in recent audits[20]. - The company faces risks in drug development due to long cycles and high investment, with potential clinical trial failures impacting profitability[148]. - The company is implementing measures to mitigate foreign exchange risks, including optimizing foreign currency allocation and using financial instruments to lock in exchange rates[151]. - The company is closely monitoring international political and economic environments to manage risks associated with its international operations[152]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, enhancing its internal control systems[158]. - The board of directors consists of 8 members, including 3 independent directors, ensuring compliance with governance requirements[159]. - The company has established a supervisory board consisting of 3 members, including 1 employee representative, complying with relevant laws and regulations[160]. - The company emphasizes transparency and investor relations, having issued over 100 reports, including resolutions and regular reports, in 2024[160]. - The company has committed to enhancing its information disclosure management system in accordance with regulatory requirements[187]. Employee Management - The total number of employees at the end of the reporting period is 4,098, with 68 in the parent company and 4,030 in major subsidiaries[193]. - The company employs 1,564 production personnel, 935 sales personnel, 832 technical personnel, 157 financial personnel, and 610 administrative personnel[193]. - The educational background of employees includes 29 with a doctorate, 241 with a master's degree, 1,379 with a bachelor's degree, 1,152 with an associate degree, and 1,297 with a technical secondary school education or below[193]. - The company has optimized its compensation plan for high-performing employees, providing competitive salary policies to maintain industry leadership[194]. - Annual training programs are implemented based on the principle of "differentiation by person and position," covering various employee categories[195]. Strategic Initiatives - The company plans to expand its market presence through strategic partnerships and acquisitions in the next fiscal year[171]. - The company aims to achieve a market expansion strategy that targets a 20% increase in market share by 2025[171]. - The company plans to establish a new international innovation center in Shanghai, set to commence operations in the second half of 2025[137]. - The company is focused on expanding its market presence and enhancing its product pipeline through strategic R&D initiatives[174].

亿帆医药股份有限公司 关于控股子公司再次通过高新技术企业认定的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：002019 证券简称：亿帆医药 公告编号：2025-017 二、对公司的影响 2025年4月23日 本次认定系上海亿一原《高新技术企业证书》有效期满后进行的重新认定。 根据《中华人民共和国企业所得税法》《高新技术企业认定管理办法》等相关规 定，上海亿一可连续三年（2024 年—2026 年）享受国家关于高新技术企业所得 税的优惠政策，即按 15%的税率缴纳企业所得税。 亿帆医药股份有限公司（以下简称"公司"）控股子公司亿一生物医药开发 （上海）有限公司（以下简称"上海亿一"）于2025年4月22日收到由上海市科 学技术委员会、上海市财政局和国家税务总局上海市税务局联合颁发的《高新技 术企业证书》，具体如下： 一、证书相关情况 亿帆医药股份有限公司董事会 | 企业名称 | 证书编号 | 发证时间 | 有效期 | | --- | --- | --- | --- | | 亿一生物医药开发（上海）有限公司 | GR202431003754 | ...

迈入麻精药市场，注入成长新动能。氢溴酸依他佐辛注射液是一种中枢性镇痛药（尤其是癌痛及手术后 疼痛），通过与κ－阿片受体结合抑制痛觉传导。目前国内镇痛药物主要包括地佐辛、喷他佐辛、纳布 啡和布托啡诺等，2023 年国内重点样本医院中镇痛药物（镇痛药物包含了麻醉用镇痛药物与止痛药） 销售规模约190 亿元，空间广阔，且因严格管制的原因具有高进入壁垒。本次获批是公司首个麻精类药 品获批上市，标志着公司进入麻精类药品领域，也标志着公司成功实现了首个管制类药品从研发到生产 再到销售的全链条打通。新市场、新领域、新产品将为公司发展持续注入新动能。 事件：公司发布《关于获得药品注册证书的公告》，披露其全资子公司合肥亿帆生物制药有限公司于 2025 年4月8日收到国家药品监督管理局核准签发的氢溴酸依他佐辛注射液《药品注册证书》。 公司氢溴酸依他佐辛注射液获批上市。氢溴酸依他佐辛注射液是由公司全资子公司合肥亿帆生物制药有 限公司自主研发并生产的麻精类药物。公司于2023 年6 月向CDE 递交了药品上市许可申请，同年7月获 得受理，后于2023 年9 月收到NMPA 签发的《麻醉药品和精神药品试验研究立项批件》，最终于2025 ...

Core Viewpoint - Yifan Pharmaceutical has received the drug registration certificate for Hydrochloride Etizolam Injection, marking its entry into the controlled substance market and enhancing its product portfolio [1][4]. Group 1: Drug Registration Information - The drug name is Hydrochloride Etizolam Injection, classified as a chemical drug of category 3 [2][3]. - The approval conclusion states that the product meets the requirements for drug registration according to Chinese regulations [1][2]. - The drug registration certificate was issued on April 8, 2025, with a validity period until March 31, 2030 [3]. Group 2: Product Overview - Hydrochloride Etizolam Injection is indicated for pain relief, particularly for cancer pain and postoperative pain [2]. - The company submitted the drug application in June 2023, received acceptance in July 2023, and obtained the research approval for controlled substances in September 2023 [2]. - The product is the first of its kind in China to pass the consistency evaluation for generic drugs [2]. Group 3: Market and Financial Impact - The domestic sales of Hydrochloride Etizolam Injection reached 128 million yuan in 2023 [2]. - The company has invested approximately 10.02 million yuan in the research and development of this product [2]. - The approval of this product is expected to positively impact the company's performance and enhance its competitiveness in the pharmaceutical sector [4].